To assess the anti-tumor functionality of CAR-T cells expressing this CCR, we constructed two distinct CAR-T cell models: MSLN CAR targeting lung cancer cells (Fig. 1B) and CD19 CAR targeting hematological malignancies (Fig.S1A). Here, CD19 is linked to hematologic disorder.